Herron JM - Search Results

1

Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children.

Brannan MD, Herron JM, Affrime MB. Brannan MD, et al. Among authors: herron jm. Clin Ther. 1997 Nov-Dec;19(6):1330-9. doi: 10.1016/s0149-2918(97)80008-2. Clin Ther. 1997. PMID: 9444443 Clinical Trial.

2

Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis.

Brannan MD, Herron JM, Reidenberg P, Affrime MB. Brannan MD, et al. Among authors: herron jm. Clin Ther. 1995 Jul-Aug;17(4):637-47. doi: 10.1016/0149-2918(95)80040-9. Clin Ther. 1995. PMID: 8565027 Clinical Trial.

3

A systemic bioactivity comparison of double-strength and regular-strength beclomethasone dipropionate MDI formulations.

Brannan MD, Herron JM, Reidenberg P, Affrime MB. Brannan MD, et al. Among authors: herron jm. Ann Allergy Asthma Immunol. 1998 Jan;80(1):39-44. doi: 10.1016/S1081-1206(10)62937-7. Ann Allergy Asthma Immunol. 1998. PMID: 9475565 Clinical Trial.

4

The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years.

Salmun LM, Herron JM, Banfield C, Padhi D, Lorber R, Affrime MB. Salmun LM, et al. Among authors: herron jm. Clin Ther. 2000 May;22(5):613-21. doi: 10.1016/S0149-2918(00)80048-X. Clin Ther. 2000. PMID: 10868558 Clinical Trial.

5

Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.

Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM. Affrime MB, et al. Among authors: herron jm. Chest. 2000 Dec;118(6):1538-46. doi: 10.1378/chest.118.6.1538. Chest. 2000. PMID: 11115437 Clinical Trial.

6

Desloratadine demonstrates dose proportionality in healthy adults after single doses.

Gupta S, Banfield C, Affrime M, Marco A, Cayen M, Herron J, Padhi D. Gupta S, et al. Clin Pharmacokinet. 2002;41 Suppl 1:1-6. doi: 10.2165/00003088-200241001-00001. Clin Pharmacokinet. 2002. PMID: 12169040 Clinical Trial.

7

Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.

Banfield C, Herron J, Keung A, Padhi D, Affrime M. Banfield C, et al. Clin Pharmacokinet. 2002;41 Suppl 1:37-44. doi: 10.2165/00003088-200241001-00006. Clin Pharmacokinet. 2002. PMID: 12169045 Clinical Trial.

8

Antihypertensive effect of dilevalol is directly related to dose and plasma concentrations.

Given BD, Perentesis G, Christopher JD, Herron J, Patrick JE, Kramer WG, Affrime MB. Given BD, et al. Am J Cardiol. 1989 Jun 5;63(19):12I-16I. doi: 10.1016/0002-9149(89)90122-7. Am J Cardiol. 1989. PMID: 2729123 Clinical Trial.

9

Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis.

Kosoglou T, Cutler DL, Staudinger H, Herron JM. Kosoglou T, et al. Among authors: herron jm. Chest. 2010 Jan;137(1):115-21. doi: 10.1378/chest.09-0235. Epub 2009 Sep 11. Chest. 2010. PMID: 19749003 Clinical Trial.

10

Safety of desloratadine syrup in children.

Bloom M, Staudinger H, Herron J. Bloom M, et al. Curr Med Res Opin. 2004 Dec;20(12):1959-65. doi: 10.1185/030079904x14148. Curr Med Res Opin. 2004. PMID: 15701213 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters